Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01385371
Other study ID # P08067
Secondary ID MK-7243-001
Status Completed
Phase Phase 3
First received April 6, 2011
Last updated September 2, 2015
Start date June 2011
Est. completion date August 2012

Study information

Verified date September 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms. Participants will receive either the sublingual grass tablet or a placebo tablet during the study. It is expected that those participants receiving the active sublingual grass tablet will have less hayfever symptoms and need less medications to treat hayfever symptoms during the grass pollen season.


Recruitment information / eligibility

Status Completed
Enrollment 1501
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 65 Years
Eligibility Inclusion Criteria:

- Must have a clinical history of significant allergic rhinoconjunctivitis to grass (with or without asthma)

- Must have a positive skin prick test response to Phleum pratense (Timothy grass)

- Must be positive for specific immunoglobulin E (IgE) against Phleum pratense (Timothy grass)

- Must have an forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at

Screening

- Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal

limits or clinically acceptable to the investigator/sponsor

Exclusion Criteria:

- Has a clinical history of symptomatic seasonal allergic rhinitis and/or asthma due to another allergen during or potentially overlapping the GPS

- Has a clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed

- Has received an immunosuppressive treatment within 3 months prior to the Screening Visit

- Has a clinical history of severe asthma

- Has a history of anaphylaxis with cardiorespiratory symptoms

- Has a history of self-injectable epinephrine use

- Has a history of chronic urticaria and angioedema

- Has a clinical history of chronic sinusitis during the 2 years prior to the Screening Visit

- Has current severe atopic dermatitis

- Is breast-feeding, pregnant, or intending to become pregnant

- Had previous treatment by immunotherapy with any grass pollen allergen for more than 1 month within the 5 years prior to the Screening Visit

- Ongoing treatment with any specific immunotherapy at the time of the Screening Visit

- Has a known history of allergy, hypersensitivity or intolerance to the ingredients of the study drug (except for Phleum pratense), rescue medications, or self-injectable epinephrine

- Has any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study. Specific examples include but are not limited to hypertension being treated with beta blockers, coronary artery disease, arrhythmia, stroke, ocular conditions requiring topical beta blockers, any condition requiring the use of beta blockers

- Has used any investigational drugs within 30 days of the Screening Visit

- Is participating in any other clinical study

- Is a family member of the investigational study staff conducting this study

- Is unable to meet medication washout requirements

- Is unlikely to be able to complete the trial, for any reason, or likely to travel for extended periods of time during the GPS, which in the opinion of the investigator will compromise the data

- Has a clinically significant abnormal vital sign or laboratory value that would preclude participation in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Grass (Phleum pratense) pollen allergen extract
One dissolving tablet sublingually once daily
Placebo for SCH 697243
One dissolving tablet sublingually once daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014 Feb;112(2):1 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS) The total combined score was the sum of the rhinoconjunctivitis DSS and rhinoconjunctivitis DMS for the entire GPS (total score range: 0 to 54), with a lower score representing less rhinoconjunctivitis symptoms and use of medications.
For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms.
For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis.
Entire GPS (expected average duration of 5 to 6 weeks) No
Secondary Average Rhinoconjunctivitis DSS Over the Entire GPS For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms. Entire GPS (expected average duration of 5 to 6 weeks) No
Secondary Average Total Combined Rhinoconjunctivitis DSS and Rhinoconjunctivitis DMS Over the Peak GPS The total combined score was the sum of the rhinoconjunctivitis DSS and rhinoconjunctivitis DMS for the entire GPS (total score range: 0 to 54), with a lower score representing less rhinoconjunctivitis symptoms and use of medications.
For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms.
For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis.
Peak GPS (expected average duration of 2 weeks) No
Secondary Average Rhinoconjunctivitis Quality of Life Questionnaire With Standardized Activities for Participants =12 Years of Age (RQLQ12+) Over the Peak GPS The RQLQ12+ consists of 7 domains: Activities, Sleep, Non-Nose/Eye Symptoms, Practical Problems, Nasal Symptoms, Eye Symptoms, Emotional. Participants reflect on their experience over the previous 7 days and assess 28 items on a scale of 0 to 6 (0=Not troubled, 6=Extremely troubled; score range: 0-6 [mean of all domain scores]), with a higher score indicating more significant impairment due to seasonal allergic rhinoconjunctivitis. Peak GPS (expected average duration of 2 weeks) No
Secondary Average Rhinoconjunctivitis DMS Over the Entire GPS For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis. Entire GPS (expected average duration of 5 to 6 weeks) No
Secondary Average Rhinoconjunctivitis DSS Over the Peak GPS For rhinoconjunctivitis DSS, participants assessed a total of 6 rhinoconjunctivitis symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes) each on a scale of 0 to 3 (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms; score range: 0 to 18), with a lower score representing less rhinoconjunctivitis symptoms. Peak GPS (expected average duration of 2 weeks) No
Secondary Average Rhinoconjunctivitis DMS Over the Peak GPS For rhinoconjunctivitis DMS, participants reported their use of specific rescue medications with specific scores assigned to each medication (score range: 0 to 36), with a lower score representing less use of medications for rhinoconjunctivitis. Peak GPS (expected average duration of 2 weeks) No
Secondary Average Paediatric Standardised Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Overall Score Over the Peak GPS (Participants 6 to <12 Years of Age) For PRQLQ, participants assessed a total of 19 items within 5 domains: Nose Symptoms, Eye Symptoms, Practical Problems, Activity Limitation and Other Symptoms, each on a scale of 0 to 6 (0=Not troubled, 6=Extremely troubled; score range: 0 to 6 [mean of all domain scores]), with a higher score indicating more significant impairment due to seasonal allergic rhinoconjunctivitis. Peak GPS (expected average duration of 2 weeks) No
See also
  Status Clinical Trial Phase
Completed NCT00783198 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) Phase 2/Phase 3
Completed NCT00770315 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Phase 3
Recruiting NCT06229379 - The Effects of a Large Language Model on Clinical Questioning Skills N/A
Not yet recruiting NCT03631108 - Feasibility Study and Preliminary Application Study on Iris OCTA
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Completed NCT00978029 - Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) Phase 2
Completed NCT00550550 - Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Phase 3
Completed NCT00562159 - Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Phase 3
Withdrawn NCT02795273 - Efficacy and Safety of Grass-SPIRE Registration Study Phase 2/Phase 3
Not yet recruiting NCT01600365 - Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus Phase 3
Completed NCT00567918 - Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Phase 3
Completed NCT04374656 - Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT02472223 - Reducing Adenoviral Patient Infected Days N/A
Completed NCT00001734 - Screening for NEI Clinical Studies N/A
Completed NCT00623701 - Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation Phase 3
Completed NCT00581542 - Moxifloxacin vs. Polytrim for Conjunctivitis Phase 4
Completed NCT04287608 - Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
Completed NCT04984941 - Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
Completed NCT00921895 - A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis N/A